

Contents

ACKNOWLEDGMENTS	ix
ACRONYMS AND ABBREVIATIONS	xiii
SUMMARY	1
1 INTRODUCTION	15
Background and Terms, 17	
Intellectual Property and Public Health, 18	
TRIPS and the Doha Declaration, 18	
Patent and Trademark Infringement, 20	
Competing Meanings of the Term Counterfeit, 22	
Substandard and Falsified Drugs, 24	
The Problem of Unregistered Medicines, 26	
A Proposed Vocabulary, 28	
Drug Quality Standards, 30	
Pharmacopeia, 30	
Registration Agencies and National Pharmaceutical	
Authorities, 31	
References, 48	
2 THE EFFECTS OF FALSIFIED AND SUBSTANDARD DRUGS	55
Public Health Consequences, 55	
Poisoning, 55	
Untreated Disease, Disease Progression, and Death, 57	

	Medications for Chronic Diseases, 58	
	Medications for Infectious Diseases, 60	
	Treatment Failure, 62	
	Antimicrobial Resistance, 63	
	Antimalarial Resistance, 65	
	Other Antiparasitic Resistance, 67	
	Economic and Social Consequences, 67	
	Costs to the Health System, 68	
	Social and Developmental Costs, 72	
	References, 78	
3	THE MAGNITUDE OF THE PROBLEM	85
	Industry and Government Data, 85	
	The Pharmaceutical Security Institute Incident Reporting System, 86	
	Government and Intergovernmental Investigations, 90	
	The FDA Office of Criminal Investigations, 90	
	International Police Investigations, 92	
	Case Reports and Convenience Samples, 94	
	Case Reports, 95	
	Convenience Samples, 96	
	Antimicrobial Drugs, 96	
	Systematic Random Samples of Drug Quality, 100	
	A Need for More Field Surveys, 102	
	Global Prevalence Estimates, 103	
	The WHO Global Capacity-Building Project, 107	
	References, 134	
4	CAUSES OF FALSIFIED AND SUBSTANDARD DRUGS	137
	Reasons for Substandard Drugs, 137	
	Uneven Manufacturing Quality, 137	
	The IFC and OPIC, 142	
	Tiered Production, 144	
	Procurement and Substandard Medicines, 146	
	Applying the Model Quality Assurance System to Secondary Procurement, 152	
	Reasons for Falsified Drugs, 153	
	Corruption and Organized Crime, 154	
	Enforcement and Punishment, 157	
	Reasons for Both, 162	
	Expense and Scarcity, 162	
	Reducing the Costs of Market Authorization, 165	
	Weak Regulatory Systems, 166	

	Gaps in Regulatory Oversight, 171	
	Lack of Awareness and Action, 173	
	Uneven Awareness, 173	
	Public Action, 176	
	References, 187	
5	WEAKNESSES IN THE DRUG DISTRIBUTION CHAIN	197
	An Overview of Drug Distribution in Developed and Developing Countries, 197	
	The Wholesale System, 203	
	The U.S. Wholesale Market, 208	
	The Wholesale Market in Low- and Middle-Income Countries, 209	
	Drug Diversion, 210	
	Pilfering and Heists, 211	
	Drug Resale and Late Diversion, 213	
	Tracking and Tracing Products Through the Supply Chain, 214	
	Barcodes, 215	
	Electronic Product Codes and Radio Frequency Identification, 217	
	Mobile Verification, 218	
	Medicines Retail, 222	
	Unregistered Pharmacies in Low- and Middle-Income Countries, 223	
	Shortage of Quality-Assured Drug Shops, 224	
	Shortage of Trained Pharmacy Staff, 224	
	Improving Retail, 228	
	Pharmaceutical Task Shifting, 229	
	Giving Incentives to Pharmaceutical Personnel, 232	
	Internet Pharmacies in Middle- and High-Income Countries, 233	
	The Legality of Internet Drugs Retail, 233	
	The Attraction of Internet Pharmacies, 236	
	Distinguishing Rogue Pharmacies from Legitimate Ones, 238	
	References, 243	
6	DETECTION TECHNOLOGY	255
	Qualitative and Quantitative Methods, 255	
	Overview of Detection, Screening, and Analytical Techniques, 257	
	Visual Inspection and Package Technologies, 257	
	Physical and Bulk Property Testing, 260	
	Colorimetry and Other Chemical Testing, 261	
	Chromatography, 261	

Spectroscopy, 265	
Mass Spectrometry, 271	
Emerging Technologies, 273	
Using Technology, 274	
Combining Techniques, 277	
Using Technology in Developing Countries, 279	
Field Technologies, 279	
Detection in Every Setting, 281	
The Technological Landscape, 284	
References, 290	

7	AN INTERNATIONAL CODE OF PRACTICE FOR FALSIFIED AND SUBSTANDARD MEDICINES	295
	The Role of the WHO, 297	
	Engaging Stakeholders, 298	
	Content of the Code, 300	
	International Surveillance, 300	
	Medicines Regulation, 301	
	Law Enforcement, 303	
	Compliance by States and Stakeholders, 304	
	References, 305	

APPENDIXES

A	GLOSSARY	309
B	COMMITTEE BIOGRAPHIES	331
C	MEETING AGENDAS	339